Literature DB >> 27541041

Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.

Kazuaki Chayama1,2,3, Clair Nelson Hayes4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27541041     DOI： 10.1007/s00535-016-1252-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  7 in total

1.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Mikio Zeniya; Etsuko Iio; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2016-02-12       Impact factor: 7.527

2.  Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.

Authors:  Hiromitsu Kumada; Fumitaka Suzuki; Yoshiyuki Suzuki; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Shigetoshi Fujiyama; Takayoshi Ito; Yoshito Itoh; Etsuko Tamura; Tomoko Ueki; Hiroki Ishikawa; Wenhua Hu; Fiona McPhee; Misti Linaberry; Eric Hughes
Journal:  J Gastroenterol Hepatol       Date:  2016-01       Impact factor: 4.029

3.  Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.

Authors:  Y Kawakami; M Imamura; H Ikeda; M Suzuki; K Arataki; M Moriishi; N Mori; K Kokoroishi; Y Katamura; T Ezaki; T Ueno; K Ide; T Masaki; H Ohdan; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-27       Impact factor: 3.728

4.  Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.

Authors:  Goki Suda; Mineo Kudo; Atsushi Nagasaka; Ken Furuya; Yoshiya Yamamoto; Tomoe Kobayashi; Keisuke Shinada; Miki Tateyama; Jun Konno; Yoko Tsukuda; Kazushi Yamasaki; Megumi Kimura; Machiko Umemura; Takaaki Izumi; Seiji Tsunematsu; Fumiyuki Sato; Katsumi Terashita; Masato Nakai; Hiromasa Horimoto; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2016-01-14       Impact factor: 7.527

5.  Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Authors:  Hiromitsu Kumada; Yoshiyuki Suzuki; Kenji Ikeda; Joji Toyota; Yoshiyasu Karino; Kazuaki Chayama; Yoshiiku Kawakami; Akio Ido; Kazuhide Yamamoto; Koichi Takaguchi; Namiki Izumi; Kazuhiko Koike; Tetsuo Takehara; Norifumi Kawada; Michio Sata; Hidetaka Miyagoshi; Timothy Eley; Fiona McPhee; Andrew Damokosh; Hiroki Ishikawa; Eric Hughes
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

6.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Authors:  Hiromitsu Kumada; Kazuaki Chayama; Lino Rodrigues; Fumitaka Suzuki; Kenji Ikeda; Hidenori Toyoda; Ken Sato; Yoshiyasu Karino; Yasushi Matsuzaki; Kiyohide Kioka; Carolyn Setze; Tami Pilot-Matias; Meenal Patwardhan; Regis A Vilchez; Margaret Burroughs; Rebecca Redman
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

7.  Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.

Authors:  Kazuaki Chayama; Kazuo Notsumata; Masayuki Kurosaki; Ken Sato; Lino Rodrigues; Carolyn Setze; Prajakta Badri; Tami Pilot-Matias; Regis A Vilchez; Hiromitsu Kumada
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.